$377 Million is the total value of CHI Advisors LLC's 24 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PLRX | Sell | PLIANT THERAPEUTICS INC | $79,848,812 | +30.3% | 3,001,835 | -5.3% | 21.20% | +29.9% |
| VECT | Sell | VECTIVBIO HLDG AG | $44,724,170 | -6.0% | 5,255,484 | -4.3% | 11.87% | -6.3% |
| LRMR | Sell | LARIMAR THERAPEUTICS INC | $12,440,580 | -13.3% | 2,746,265 | -20.9% | 3.30% | -13.6% |
| INZY | Sell | INOZYME PHARMA INC | $7,690,754 | +232.2% | 1,342,191 | -39.1% | 2.04% | +231.0% |
| DTIL | Sell | PRECISION BIOSCIENCES INC | $2,614,857 | -38.1% | 3,469,820 | -2.3% | 0.69% | -38.3% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $2,157,982 | -83.8% | 689,451 | -63.5% | 0.57% | -83.8% |
| FRLN | Sell | FREELINE THERAPEUTICS HLDGSsponsored ads | $2,151,886 | -5.9% | 4,729,419 | -1.8% | 0.57% | -6.2% |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $2,128,856 | +5.0% | 2,339,402 | -1.9% | 0.56% | +4.6% |
| PLRX | Exit | PLIANT THERAPEUTICS INCcall | $0 | – | -30,000 | -100.0% | -0.01% | – |
| LABD | Exit | DIREXION SHS ETF TRdaily s&p biotec | $0 | – | -25,000 | -100.0% | -0.12% | – |
| GTHX | Exit | G1 THERAPEUTICS INC | $0 | – | -333,945 | -100.0% | -0.48% | – |
| ORTX | Exit | ORCHARD THERAPEUTICS PLCspon ads | $0 | – | -7,987,396 | -100.0% | -0.79% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.